ΠΠ½Π΄ΠΎΡΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Ρ aITEL1296 Π½Π° ΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π² ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΊΡΠ΅Π½ΠΎΠ³ΡΠ°ΡΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ , ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ ΠΈΠ· ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠΎΠ² ΠΏΠΎ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠ°Π·Ρ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΅Π΅ Π³ΠΎΠΌΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΡΡΠ±ΡΠ΅Π΄ΠΈΠ½ΠΈΡΠ°ΠΌΠΈ ΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ°, ΡΠ΄Π°Π»ΠΎΡΡ Π²ΡΡΠ²ΠΈΡΡ ΡΡΠ°ΡΡΠΊΠΈ Π³ΠΎΠΌΠΎΠ»ΠΎΠ³ΠΈΠΈ Π»ΠΈΡΡ Π² ΠΌΠΎΠ»Π΅ΠΊΡΠ»Π΅ hTERT. ΠΡΠΈ Π΄Π°Π½Π½ΡΠ΅ Π±ΡΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π΄Π»Ρ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ aITEL1296 Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΠΎΠΉ hTERT. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²Π΅ΡΠΎΡΡΠ½ΡΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ΅Π»Π΅Π½ΡΠΊΠΈΠΉ Π. Π. ΠΠ»Π΅ΠΌΠ΅Π½ΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ°. — Π. — ΠΠ΅Π΄Π³ΠΈΠ·. — 1961. — 152 Ρ.
- ΠΠ»ΡΡ ΠΎΠ΅ Π. Π., ΠΠΈΠΌΠ½ΠΈΠΊ Π. Π., ΠΠΎΡΠ΄Π΅Π΅Π² Π‘. Π. ΠΈ Π΄Ρ. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΡ ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌ Π΄Π»Ρ Π°Π½Π°Π»ΠΈΠ·Π° ΡΠ΅Π»ΠΎΠΌΠ΅ΡΠ°Π·Ρ // ΠΠ»Π»Π΅ΡΠ³ΠΈΡ, Π°ΡΡΠΌΠ° ΠΈ ΠΊΠ»ΠΈΠ½, ΠΈΠΌΠΌΡΠ½ΠΎΠ». 1999. — N 9. — Π‘. 173 — 175.
- ΠΠ»Π°Π½Ρ Π‘. ΠΠ΅Π΄ΠΈΠΊΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° (ΠΏΠ΅Ρ. Ρ Π°Π½Π³Π».), ΠΡΠ°ΠΊΡΠΈΠΊΠ°, Π. 1998.
- ΠΠΎΡΠΌΠ°Π½ Π. Π. ΠΡΠ½ΠΎΠ²Ρ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΉ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π.: ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π° — 2006. — 512 Ρ.
- ΠΡΠ΅ΡΠΎΠ²ΠΈΡ Π. Π. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² ΡΠ½Π·ΠΈΠΌΠΎΠ»ΠΎΠ³ΠΈΡ. Π., «ΠΠ°ΡΠΊΠ°», 1974 Π³.
- ΠΠ°Π»Π°ΡΠ΅Π½ΠΊΠΎ Π. Π. ΠΠ΅ΠΆΠ»ΠΈΠ½Π΅ΠΉΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΌΡΠΆΡΠΊΠΈΡ ΠΏΠΎΠ»ΠΎΠ²ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Ρ ΠΌΡΡΠ΅ΠΉ ΠΊ ΠΈΠ½Π΄ΡΠΊΡΠΈΠΈ Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΡΡ Π»Π΅ΡΠ°Π»Π΅ΠΉ ΡΠΈΠΎΡΠΎΡΡΠ°ΠΌΠΈΠ΄ΠΎΠΌ. // ΠΠ΅Π½Π΅ΡΠΈΠΊΠ°. 1980. — Π’. XVI — № 9. — Ρ. 1577 — 1583.
- Π ΠΎΡΡ Π£. ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°Π»ΠΊΠΈΠ»ΠΈΡΡΡΡΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°. Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°. -1964.-259 Ρ.
- Π’ΡΠ΅ΡΠ°Π»ΠΈΠ½ Π. Π. Π‘ΠΎΠ²Π΅ΡΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΏΠ»Π°ΡΠΈΠ½. Π’ΠΎΠΊΡΠΈΠΊΠΎΠ»ΠΎΠ³ΠΈΡ, ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΠΊΠ° ΠΈ ΡΠ½ΡΡΠΈΠ΅ Π½Π΅ΡΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ (ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅). ΠΠΈΡΡ. ΠΊΠ°Π½Π΄. ΠΌΠ΅Π΄. Π½Π°ΡΠΊ. Π. -1983.- 131 Ρ.
- Π£ΡΠ±Π± Π. ΠΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ°, ΠΏΠ΅Ρ. Ρ Π°Π½Π³Π»., Π., 1966 Π³.
- Π₯ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π§Ρ ΠΈ Π. ΠΠ΅ΠΠΈΡΡ -ΠΌΠ»Π°Π΄ΡΠ΅Π³ΠΎ. Π.: ΠΡΠ°ΠΊΡΠΈΠΊΠ°. — 2009. — 455 Ρ.
- ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ http://msds.chem.ox.ac.uk
- A be N., Watanabe Π’., Nakashima Π. et al. Quantitative analysis of telomerase activity: a potential diagnostic tool for colorectal carcinoma // Hepatogastroenterology. 2001. -Vol. 48. — P. 692 — 695.
- Ahmed S., Passos J. F., Birket M. J. et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress//J. Cell Sci. 2008.-Vol. 121.-P. 1046- 1053.
- Aldous W. K., Grabill N. R. A fluorescent method for detection of telomerase activity // Diagn. Mol. Pathol. 1997. — V. 6. — P. 102 — 110.
- Azzalin Π‘. M., Reichenbach P., Khoriauli L. et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends // Science 2007. — V. 318. — P. 798 — 801.
- Berg K., Selbo P. K., Prasmickaite L. et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol // Cancer Res. 1999.-V. 59.-P. 1180- 1183.
- Chabner B. A., Longo D. L. Cancer Chemotherapy and Biotherapy: Principles and Practice. — 3rd ed., Philadelphia: Lippincott-Raven. -2001.-P. 678−699.
- Chen B., Liang J., Tian X. et al. G-quadruplex structure: a target for anticancer therapy and a probe for detection of potassium // Biochemistry (Mosc). 2008. — V. 73. — P. 853 — 861.
- Chen Y. J., Sheng W. Y, Huang P. R. et al. Potent inhibition of human telomerase by U-73 122 // J Biomed Sci. 2006. — V. 13. — P. 667 — 674.
- Chen Z., Koeneman K. S., Corey D. R. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells // Cancer Res. 2003. — V. 63. — P. 5917 — 5925.
- Chomezynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction // Anal Biochem -1987.-V. 162.-P. 156- 159.
- Colangelo D., GhigliaA., Ghezzi A. et al. Water-soluble benzoheterocycle triosmium clusters as potential inhibitors of telomerase enzyme // J. Inorg. Biochem. 2005. — V. 99. — P. 505 — 512.
- Counter C. M., Botelho F. M., Wang P. et al. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes // J. Virol. 1994. — V. 68. -P. 3410−3414.
- Crabbe L., Jauch A., Naeger C. M. et al. Telomere dysfunction as a cause of genomic instability in Werner syndrome // Proc .Natl. Acad. Sci. U S A. 2007. — V. 104.- P. 2205 — 2210.
- Dudognon C., Pendino F., Hillion J. et al. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance // Oncogene. 2004. -Vol. 23.-P. 7469−7474.
- Dunham M. A., Neumann A. A., Fasching C. L. et al. Telomere maintenance by recombination in human cells // Nat. Genet. 2000. — V. 26.-P. 447−450.
- El-Daly H., Kull M., Zimmermann S. et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532//Blood.-2005.-V. 105.-P. 1742−1749.
- Erba E., Bergamaschi D., Ronzoni S. et al. Mode of action of thiocoraline, a natural marine compound with anti-tumour activity // Br. J. Cancer. -1999.-V. 80.-P. 971 -980.
- Fajkus J., Fulneckova J., Hulanova M. et al. Plant cells express telomerase activity upon transfer to callus culture, without extensivelychanging telomere lengths // Mol. Gen. Genet. 1998. — V. 260. — P. 470 -474.
- Feng J., Funk W. D., Wang S. S. et al. The RNA component of human telomerase//Science. 1995.-V. 269.-P. 1236- 1241.
- Fuster J. J., Andres V. Telomere biology and cardiovascular disease // Circ. Res. 2006. — V. 99. — P. 1167 — 1180.
- Georgiadis M. M., Jessen S. M, Ogata Π‘. M. et al. Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase // Structure. 1995. — V. 3. — P. 879 — 892.
- Glukhov A. I., Zimnik Π. V., Gordeev S. A. et al. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides // Biochem. Biophys. Res. Commun. 1998. -V. 248. — P. 368 — 371.
- Goodsell D. S. The molecular perspective: 1-asparaginase // Stem Cells. -2005.-Vol. 23.-P. 710−711.
- Graves A. P., Devleena M., Shivakumar S. E. et al. Rescoring Docking Hit Lists for Model Cavity Sites: Predictions and Experimental Testing // J. Mol. Biol. 2008. — V. 377. — P. 914 — 934.
- Griffith J. D., Comeau L., Rosenfield S. et al. Mammalian telomeres end in a large duplex loop // Cell. 1999. — V. 97. — P. 503 — 514.
- Hamilton S. E., Pitts A. E., Katipally R. R. et al. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning // Biochemistry. 1997. — V. 36. — P. 11 873- 11 880.
- Hanahan D, Weinberg R. A. Hallmarks of cancer: the next generation // Cell. 2011. — V. 144. — P. 646 — 674.51 .Harrington L. Biochemical aspects of telomerase function // Cancer Lett. -2003 V. 194.-P. 139−154.
- Hayakawa N., Nozawa K, Ogawa A. et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro // Biochemistry. 1999.-V. 38.-N35.-P. 11 501 — 11 507.
- Itahana K., Campisi J., Dimri G. P. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay // Methods Mol. Biol. 2007. -Vol. 371.-P. 21 -31.
- Kim N. W., Piatyszek M. A., Prowse K. R. et al. Specific association of human telomerase activity with immortal cells and cancer // Science. -1994.-V. 266.-P. 2011 -2015.
- Kondo S., Kondo Y, Li G. et al. Targeted therapy of human malignant glioma in a mouse model by 2−5A antisense directed against telomerase RNA // Oncogene. 1998. — V. 16. — P. 3323 — 3330.
- Kosciolek B. A., Kalantidis K., Tabler M. et al. Inhibition of telomerase activity in human cancer cells by RNA interference // Mol. Cancer Ther. -2003.-V. 2.-P. 209−216.
- Kraemer K., Fuessel S., Schmidt U. et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells // Clin. Cancer Res. 2003. — V. 9. — P. 3794 — 3800.
- Krupp G., Kuhne K., Tamm S. et al. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay//Nucleic Acids Res. 1997.-V. 25.-P. 919 — 921.
- Li H., Zhao L. L., Funder J. W. et al. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells // J. Biol. Chem. 1997. — V. 272. — P. 16 729 — 16 732.
- Lin F. T. Preclinical pharmacologic evaluation of bleomycin A6. Zhonghua Zhong Liu Za Zhi. 1989. — Vol. 11. — P. 257 — 259.
- Lu C., Fu W., Mattson M. P. Telomerase protects developing neurons against DNA damage-induced cell death // Brain Res. Dev. Brain. Res. -2001.-Vol. 131.-P. 167−171.
- Ludwig A., Saretzki G., Holm P. S. et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase// Cancer Res. -2001. -Vol. 61.-P. 3053−3061.
- Mata J. E., Joshi S. S., Palen B. et al. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt’s lymphoma cells in vitro and in vivo // Toxicol. Appl. Pharmacol. 1997. — V. 144. -P. 189- 197.
- Mikhail ov A., Sokolovskaya A., Yegutkin G. G. et al. CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis // J. Immunol. 2008. — V. — 181. — P. 464 — 475.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. // J. Immunol. Methods. 1983. — V. 65. — 2. — P. 55 — 63.
- Mitchell M., Gillis A., Futahashi M. et al. Structural evidence for RNA template and telomeric DNA binding by the catalytic subunit of telomerase, TERT // Nat. Struct. Mol. Biol. 2010. — Vol. 17. — P. 513 -518 .
- Montano S. P., Cote M. L., Roth M i et al. Crystal structures of oligonucleotides including the integrase processing site of the Moloney murine leukemia virus // Nucleic Acids Res. 2006. — V. 34. — P. 5353 -5360.
- Naasani I., Oh-Hashi F., Oh-Hara T. et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo // Cancer Res. 2003. — V. 63. -P. 824−830.
- Newlands E.S. Results with the EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine) Regimen in High Risk Gestational Trophoblastic Tumours, 1979 to 1989 // Br. J. Obstet. Gynaecol. 1991. — Vol. 98. — P. 550 — 557.
- Norton J. C., Piatyszek M. A., Wright W. E. et al. Inhibition of human telomerase activity by peptide nucleic acids // Nat. Biotechnol. 1996. -V. 14. — P. 615−619.
- Nowak J., Januszkiewicz D., Lewandowski K. et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients // Eur. J. Gastroenterol. Hepatol. 2003.- Vol. 15.-P. 75 -80.
- Ohnuma T., Li F. L., Holland J. F. Inhibitory effects of telomere-mimic phosphorothioate oligonucleotides on various human tumor cells in vitro // Anticancer Res. 1997. — V. 17. — P. 2455 — 2458.
- Ohyashiki K., Ohyashiki J. H., Nishimaki J. et al. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay // Cancer Res. 1997. — V. 57. — P. 2100 — 2103.
- Okamura K., Ohno M., Tsutsui T. Possible involvement of loss of imprinting in immortalization of human fibroblasts // Int. J. Oncol. -2011.-Vol. 38.-P. 903−910.
- Park J. I., Venteicher A. S., Hong J. Y. et al. Telomerase modulates Wnt signalling by association with target gene chromatin // Nature. 2009. -Vol. 460.-P. 66−72.
- Pascolo E., Wenz C., Lingner J. et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate // J. Biol. Chem. 2002. -V. 277. — P. 15 566 — 15 572.
- Pendino F., Tarkanyi I., Dudognon C. et al. // Telomeres and telomerase: Pharmacological targets for new anticancer strategies? // Curr. Cancer Drug Targets. 2006. — Vol. — 6. — P. 147 — 180.
- Perrault S. D., Hornsby P. J., Betts D. H. Global gene expression response to telomerase in bovine adrenocortical cells // Biochem. Biophys. Res. Commun. 2005. — Vol. 335 — P. 925 — 936.
- Philips F. S., Sternberg S. S., Cronin A. P. et al. Cyclophosphamide and urinary bladder toxicity // Cancer Res. 1961. — Vol. 21. — P. 1577 -1589.
- Pieters R., Hunger S. P., Boos J. et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase // Cancer. -2011.-Vol. 117.-P. 238−249.
- Pirollo K. F., Rait A., Sleer L. S. et al. Antisense therapeutics: from theory to clinical practice // Pharmacol Ther. 2003. — V. 99. — P. 55 -77.
- Pirzio L. M., Freulet-Marriere M. A., Bai Y. et al. Human fibroblasts expressing hTERT show remarkable karyotype stability even after exposure to ionizing radiation // Cytogenet. Genome Res. 2004. -Vol. 104.-P. 87−94.
- Plunkett F. J., Franzese O., Belaramani L. L. et al. The impact of telomere erosion on memory CD8+ T cells in patients with X-linked lymphoproliferative syndrome // Mech. Ageing Dev. 2005. — V. 126.-P. 855 -865.
- Podlevsky J. D., Bley C. J., Omana R. V. et al. The telomerase database // Nucleic Acids Res. 2008. — V. 36 (Database issue). — D 339 -343.
- Pruzan R., Pongracz K., Gietzen K. et al. Allosteric inhibitors of telomerase: oligonucleotide N3'~>P5' phosphoramidates // Nucleic Acids Res. 2002. — V. 30. — P. 559 — 568.
- Rahman R., Latonen L., Wiman K. G. hTERT antagonizes p53-induced apoptosis independently of telomerase activity // Oncogene. -2005. Vol. 24. — P. 1320 — 1327.
- Rizzo R. C., Aynechi T., Case D. A. et al. Estimation of Absolute Free Energies of Hydration Using Continuum Methods: Accuracy of Partial Charge Models and Optimization of Nonpolar Contributions // J. Chem. Theory Comput. 2006. — V. 2. — P. 128 — 139.
- Robart A. R., Collins K. Investigation of human telomerase holoenzyme assembly, activity, and processivity using disease-linked subunit variants // J. Biol. Chem. 2010. — V. 285. — P. 4375 — 4386.
- Rubio M. A., Davalos A. R., Campisi J. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress // Exp. Cell Res. 2004. — Vol. 298. — P. 17 — 27.
- Rudolph R., Larson D. L. Etiology and Treatment of Chemotherapeutic Agent Extravasation Injuries: A Review // J. Clin. Oncol. 1987.-Vol. 5.-P. 1116−1126.
- Saretzki G., Ludwig A., von Zglinicki T. et al. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells // Cancer Gene Ther. 2001. — V. 8. -P. 827−834.
- Savoysky E., Akamatsu K., Tsuchiya M. et al. Detection of telomerase activity by combination of TRAP method and scintillation proximity assay (SPA) // Nucleic Acids Res. 1996. — V. 24. — P. 1175 -1176.
- Schindler A., Fiedler U., Meye A. et al. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro // Int. J. Oncol. 2001. — V. 19. — P. 25 — 30.
- Schmidt P. M., Matthes E., Scheller F. W. et al. Real-time determination of telomerase activity in cell extracts using an optical biosensor // Biol. Chem. 2002. — V. 383. — P. 1659 — 1666.
- Schoeftner S. Blasco M. A. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II // Nat. Cell Biol. 2008. — V. 10. — P. 228 — 236.
- Shammas M. A., Simmons C. G., Corey D. R. et al. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells // Oncogene. 1999. — V. 18. — P. 6191 — 6200.
- Shay J. W., Bacchetti S. A survey of telomerase activity in human cancer // Eur. J. Cancer. 1997. — V. 33. — P. 787 — 791.
- Shay J. W., Van Der Haegen B. A., Ying Y et al. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SY40 large T-antigen // Exp. Cell Res. 1993. — V. 209. -P. 45−52.
- Smith L. L., Coller H. A., Roberts J. M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation // Nat Cell Biol. 2003. — Vol. 5. — P. 474 — 479.
- Smogorzewska A., van Steensel B., Bianchi A. et al. Control of human telomere length by TRF1 and TRF2 // Mol. Cell Biol. 2000. — V. 20.-P. 1659- 1668.
- Song J. S., Murase N., Demetris A. J. et al. Protection from acute cellular injury using Sleeping Beauty mediated telomerase gene transfer // Biochem. Biophys. Res. Commun. 2007. — Vol. 363. — P. 253 — 256.
- Strahl C., Blackburn E. H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines // Mol. Cell Biol. 1996. — V. 16. — P. 53 — 65.
- Stravopodis D. J., Margaritis L. H., Voutsinas G. E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex // Curr. Med. Chem. 2007. -V. 14.-P. 3122−3138.
- Tatsumoto N., Hiyama E., Murakami Y et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer // Clin. Cancer Res. 2000. -Vol. 6. — P. 2696 — 2701.
- Teng L" Specht M. C" Barden C. B. et al. Antisense hTERT inhibits thyroid cancer cell growth // J. Clin. Endocrinol. Metab. 2003. — V. 88. -P. 1362- 1366.
- Ueno T., Takahashi H., Oda M. et al. Inhibition of human telomerase by rubromycins: implication of spiroketal system of the compounds as an active moiety // Biochemistry. ~ 2000. V. 39. — P. 5995 — 6002.
- Ulaner G., Hu J., Vu T. et al. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development // Int. J. Cancer. 2001. — Vol. 91. -P. 644 — 649.
- Villa R., Folini M., Lualdi S. et al. Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells // FEBS Lett. 2000. — V. 473. — P. 241 — 248.
- Von Zglinicki T. Oxidative stress shortens telomeres // Trends Biochem. Sci. 2002. — Vol. 27 — P. 339 — 344.
- Walker P. R., Kwast-Welfeld J., Gourdeau H. et al. Relationship between apoptosis and the cell cycle in lymphocytes: roles of protein kinase C, tyrosine phosphorylation, and API // Exp. Cell Res. 1993. -V. 207. — P. 142−151. 11
- Walsby E. J., Coles S. J., Knapper S. et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. -2011.-Vol. 96.-P. 393 -399.
- Ward R. J., Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment // Mol Pharmacol. 2005. — V. 68. — P. 779 — 786.
- Wege H., Chui M. S., Le H. T. et al. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity // Nucleic Acids Res. 2003. — V. 31. — P. E3.
- Wong K. K., Chang S., Weiler S. R. et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation // Nat. Genet. 2000. — Vol. 26. — P. 85 — 88.
- Wright W. E., Shay J. W., Piatyszek M. A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increasedreliability, linearity and sensitivity // Nucleic Acids Res. 1995. — V. 23. -P. 3794−3795.
- Xu S. Q., He M., Yu H. P. et al. Bioluminescent method for detecting telomerase activity // Clin. Chem. 2002. — V. 48. — P. 1016 -1020.
- Yamakuchi M., Nakata M., Kawahara K. et al. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines // Cancer Lett. 1997. — V. 119. — P. 213 — 9.
- Yang J., Chang E., Cherry A. M. et al. Human endothelial cell life extension by telomerase expression // J. Biol. Chem. 1999. — Vol. 274. -P. 26 141−26 148.
- Yokoyama Y., Takahashi Y., Shinohara A. et al. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells // Cancer Res.1998.-V. 58.-P. 5406−5410.
- Yokoyama Y., Takahashi Y., Shinohara A. et al. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity // Biochem. Biophys. Res. Commun. 2000. — V. -273. -P. 316−321.
- Yuan F., Chen M., Hornsby P. J. Fibroblasts from Werner syndrome patients: cancer cells derived by experimental introduction of oncogenes maintain malignant properties despite entering crisis // Oncol. Rep. 2010. — Vol. 23. — P. 377 — 386.
- Zhang X., Mar V., Zhou W. et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells // Genes Dev.1999.-V. 13.-P. 2388−2399.1. ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΠΈ